It has been in fact reported that treatment with the demethylating agent decitabine may result in the re-expression of EGFR in two breast cancer cell lines, in which EGFR transcription was abolished by EGFR promoter hypermethylation. The gene discussed is EGFR; the disease is breast carcinoma.